XML 42 R9.htm IDEA: XBRL DOCUMENT v2.4.0.8
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
6 Months Ended
Jun. 30, 2013
Summary Of Significant Accounting Policies [Abstract]  
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
NOTE 2 – SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
 
Consolidation.  The condensed consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries, Isis Tele-Communications, Inc., which has no current operations, and SafeStitch LLC.  All inter-company accounts and transactions have been eliminated in consolidation.
 
Use of estimates.  The preparation of financial statements in conformity with accounting principles generally accepted in the United States (“GAAP”) requires management to make estimates and assumptions, such as useful lives of property and equipment, that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period.  Actual results could differ from those estimates. 
 
Cash and cash equivalents.  We consider all highly liquid investments with a maturity of three months or less when purchased to be cash equivalents.  The Company holds cash and cash equivalent balances in banks and other financial institutions, and includes overnight repurchase agreements collateralizing its depository bank accounts (sweep accounts) in its cash balances.  Balances in excess of Federal Deposit Insurance Corporation (“FDIC”) limitations may not be insured.
 
Allowances for Doubtful Accounts.  The Company provides an allowance for receivables it believes it may not collect in full.  Receivables are written off when they are deemed to be uncollectible and all collection attempts have ceased.  The amount of bad debt recorded each period and the resulting adequacy of the allowance for doubtful accounts at the end of each period are determined using a combination of customer-by-customer analysis of the Company’s accounts receivable each period and subjective assessments of the Company’s future bad debt exposure.
 
Inventories.  Inventories are stated at lower of cost or market using the weighted average cost method. Provisions for potentially obsolete or slow-moving inventory are made based on management’s analysis of inventory levels, obsolescence and future sales forecasts. The Company had approximately 5,707 AMID HFD units in inventory at June 30, 2013 and 5,800 units at December 31, 2012.
 
Property and equipment.  Property and equipment are carried at cost less accumulated depreciation.  Major additions and improvements are capitalized, while maintenance and repairs that do not extend the lives of assets are expensed.  Gain or loss, if any, on the disposition of fixed assets is recognized currently in operations.  Depreciation is calculated primarily on a straight-line basis over estimated useful lives of the assets. 
 
Revenue Recognition.  Revenue from product sales is recognized when persuasive evidence of an arrangement exists, the goods are shipped and title has transferred, the price is fixed or determinable, and the collection of the sales proceeds is reasonably assured. The Company’s revenue was a result of AMID HFD product sales. There were 26 and 62 AMID HFD units sold during the three and six months ended June 30, 2013 and there were 24 AMID HFD units sold for the three and six months ended June 30, 2012. In addition, there were 42 and 60 AMID HFD units used for demonstration purposes during the three and six months ended June 30, 2013 and 516 AMID HFD units were used for demonstration purposes during the three and six months ended June 30, 2012.
 
Advertising Costs.  The Company expenses all costs of advertising as incurred.  Advertising and promotional costs are included in selling, general and administrative costs and expenses for all periods presented, and totaled $0 and $520, respectively, for the three and six months ended June 30, 2013.  Advertising and promotional costs and expenses totaled $45,000 and $83,000, respectively, for the three and six months ended June 30, 2012.
 
Research and development.  Research and development costs principally represent salaries of the Company’s medical and biomechanical engineering professionals, material and shop costs associated with manufacturing product prototypes and payments to third parties for clinical trials and additional product development and testing.  All research and development costs are charged to expense as incurred.
 
Patent costs.  Costs incurred in connection with acquiring patent rights and the protection of proprietary technologies are charged to expense as incurred. 
 
Stock-based compensation.  The Company follows ASC 718 (Stock Compensation) and 505-50 (Equity-Based Payments to Non-employees), which provide guidance in accounting for share-based awards exchanged for services rendered and requires companies to expense the estimated fair value of these awards over the requisite service period.  The Company determines the fair value of the stock-based compensation awards granted as either the fair value of the consideration received or the fair value of the equity instruments issued, whichever is more reliably measurable. If the fair value of the equity instruments issued is used, it is measured using the stock price and other measurement assumptions as of the earlier of either of (1) the date at which a commitment for performance by the counterparty to earn the equity instruments is reached, or (2) the date at which the counterparty’s performance is complete.
 
Fair value of financial instruments.  Authoritative guidance defines fair value as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. The fair value hierarchy consists of three broad levels, as described below:
 
·
Level 1 - Unadjusted quoted prices in active markets that are accessible at the measurement date for identical, unrestricted assets or liabilities.
·
Level 2 - Inputs other than quoted prices included within Level 1 that are observable for the asset or liability, either directly or indirectly.
·
Level 3 - Inputs that are both significant to the fair value measurement and unobservable.
             
Long-lived assets.  Long-lived assets, such as property and equipment, are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability of assets to be held and used is measured by a comparison of the carrying amount of an asset to estimated undiscounted future cash flows expected to be generated by the asset. If the carrying amount of an asset exceeds its estimated future cash flows, then an impairment charge is recognized for the amount by which the carrying amount of the asset exceeds the fair value, or carrying amount for cost basis assets, of the asset.
 
Income taxes.  The Company follows the liability method of accounting for income taxes, which requires the recognition of deferred tax liabilities and assets for the expected future tax consequences of temporary differences between the carrying amounts and the tax bases of the assets and liabilities.  The Company’s policy is to record a valuation allowance against deferred tax assets, when the deferred tax asset is not recoverable.  The Company considers estimated future taxable income or loss and other available evidence when assessing the need for its deferred tax valuation allowance. 
 
Comprehensive income (loss).  Comprehensive income (loss) is defined as the change in equity of a business enterprise during a period from transactions and other events and circumstances from non-owner sources.  The Company’s comprehensive net loss is equal to its net loss for all periods presented.